Shares of Kura Oncology Inc. (NASDAQ:KURA) have earned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the stock, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy recommendation.
Brokerages have set a one year consensus price objective of $20.00 for the company and are predicting that the company will post ($0.41) EPS for the current quarter, according to Zacks. Zacks has also given Kura Oncology an industry rank of 91 out of 265 based on the ratings given to related companies.
A number of equities analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a report on Tuesday. Oppenheimer Holdings Inc. reiterated an “outperform” rating and issued a $16.00 price target on shares of Kura Oncology in a report on Sunday, August 14th.
A hedge fund recently bought a new stake in Kura Oncology stock. Minerva Advisors LLC bought a new stake in shares of Kura Oncology Inc. (NASDAQ:KURA) during the second quarter, according to its most recent 13F filing with the SEC. The fund bought 361,737 shares of the company’s stock, valued at approximately $977,000. Minerva Advisors LLC owned approximately 1.96% of Kura Oncology as of its most recent filing with the SEC. 43.63% of the stock is owned by institutional investors.
Kura Oncology (NASDAQ:KURA) opened at 7.05 on Tuesday. Kura Oncology has a 12-month low of $2.50 and a 12-month high of $25.00. The firm has a 50-day moving average of $5.61 and a 200 day moving average of $3.99. The firm’s market capitalization is $132.14 million.
Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Wednesday, August 10th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.34) by $0.02. On average, equities analysts predict that Kura Oncology will post ($1.58) EPS for the current year.
About Kura Oncology
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.